Home > Category > Signaling Pathways > GPCR & G Protein > GNRH Receptor > Elagolix (NBI-56418)

Elagolix (NBI-56418)

ChemLeader 98+%

Catalog No：CL2564 CAS No.：834153-87-6 MDLNo： Formula：C32H30F5N3O5 MW：631.59

Collect Share

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Chemical safety data sheet(MSDS)

Download MSDS

Inquiry Add To Cart

Product Overview
Related documents
Product details
Related literature

Product Overview

Product Name	Elagolix (NBI-56418)
CAS	834153-87-6
Formula	C32H30F5N3O5
MW	631.59
Appearance	White to off-white powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

Elagolix (formerly NBI56418; ABT620; NBI-56418; ABT-620; trade name: Orilissa) is a potent, specific, orally bioavailable, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) used for pain management. It inhibits GnRHR with a Kd of 54 pM. Elagolix was given FDA approval on July 23, 2018, to treat endometriosis-related moderate to severe pain. A short-acting GnRH antagonist, elagolix suppresses ovarian estrogen production in a dose-dependent manner, resulting in partial suppression at lower doses and complete suppression at higher doses. Because Elagolix is non-peptide and readily absorbed through the mouth, it is considered the leader of a new class of GnRH inhibitors known as second-generation inhibitors.

Related literature

Sorry, there is no relevant literature

Sorry, no related items

History

CL2564

Elagolix (NBI-56418)

834153-87-6 98+%